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Abstract
Medullary thyroid carcinoma is a neuroendocrine tumour originating from parafollicular 
C cells accounting for 5–10% of thyroid cancers. Increased understanding of disease-
specific molecular targets of therapy has led to the regulatory approval of two drugs 
(vandetanib and cabozantinib) for the treatment of medullary thyroid carcinoma. These 
drugs increase progression-free survival; however, they are often poorly tolerated and 
most treatment responses are transient. Animal models are indispensable tools for 
investigating the pathogenesis, mechanisms for tumour invasion and metastasis and 
new therapeutic approaches for cancer. Unfortunately, only few models are available for 
medullary thyroid carcinoma. This review provides an overview of the state of the art of 
animal models in medullary thyroid carcinoma and highlights future developments in this 
field, with the aim of addressing salient features and clinical relevance.
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Introduction
Medullary thyroid carcinoma (MTC) is a neuroendocrine 
tumour originating from parafollicular C cells. At the 
end of 60s, after the discovery that MTC represents a 
unique thyroid cancer, it was recognised that the tumour 
occurred either sporadically or in a hereditary form as a 
component of the type 2 multiple endocrine neoplasia 
(MEN) syndromes, MEN2A and MEN2B, and the related 
syndrome, familial MTC (FMTC). RET (REarranged during 
Transfection) proto-oncogene alterations are crucial 
events for MTC development. The most frequent RET 
alterations in MTC are activating point mutations, but 
deletions and insertions have also been reported (Romei 
et al. 2016). The clinical course of patients with MTC is 
variable, ranging from indolent to extremely aggressive, 
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and it is related to the stage of the disease at the time 
of diagnosis (Vitale et  al. 2001). Ten-year survival rates 
for patients with stages I, II, III and IV MTCs are 100%, 
93%, 71% and 21%, respectively (Modigliani et  al. 
1998). In the last decades, there has been no significant 
trend towards an earlier stage of disease at the time of 
diagnosis. Indeed, under half of the patients present with 
stage III or IV disease (Kebebew et al. 2005, Roman et al. 
2006). Surgery is the only curative treatment for MTC. 
Radiotherapy and chemotherapy play a marginal role 
in advanced MTC (Vitale et  al. 2001, Cabanillas et  al. 
2016). Somatostatin analogues are able to control the 
neuroendocrine symptoms induced by advanced MTC 
(Lupoli et  al. 1996, Vitale et  al. 2000). In recent years, 
several tyrosine kinase inhibitors (axitinib, cabozantinib, 
gefitinib, imatinib, motesanib, sorafenib, sunitinib and 
vandetanib) have been evaluated in phase I, II and III 
clinical trials of patients with advanced MTC. These drugs 
increased progression-free survival, however, with time, 
the MTC becomes resistant to these drugs and the disease 
progresses (Cabanillas et  al. 2016, Viola et  al. 2016). In 
addition, few preliminary clinical studies evaluated the 
potential beneficial effects of mTOR inhibitors in the 
treatment of MTC, showing the stabilisation of disease 
in most of patients treated with everolimus (Druce et al. 
2012, Faggiano et al. 2012, Lim et al. 2013, Schneider et al. 
2015). Therefore, in patients with advanced MTC, there is 
a critical need for more effective therapies.
Animal models are indispensable tools for 
investigating the pathogenesis, mechanisms for tumour 
invasion and metastasis and new therapeutic approaches 
for cancer. Unfortunately, only few models are available 
for MTC. This paper provides a state-of-the-art overview 
of animal models in MTC and highlights the future 
developments in this field, with the aim of addressing the 
salient features and clinical relevance.
Murine models
In the last year, several genetically engineered murine 
models of MTCs have been constructed to replicate 
this disease and related variants. These models were 
generated by overexpressing mutated oncogenic RET or 
other oncogenes in transgenic mice or through the loss of 
tumour suppressor genes (Cote et al. 2015, Kirschner et al. 
2016, Wiedemann & Pellegata 2016).
Another traditional preclinical model consists of 
implantation of MTC cell lines or tumour fragments into 
immunodeficient rodents.
Genetically engineered mouse models carrying  
RET mutations
In humans, activating mutations of RET proto-oncogene 
play a relevant role in the pathogenesis of both familial 
(MEN2A, MEN2B and FMTC) and sporadic forms of MTC. 
Germline activating mutations of RET have been reported 
in around 88–98% of familial MTCs, whereas somatic 
mutations of this gene have been detected in 23–70% 
of sporadic forms (Manfredi et al. 2016). The RET proto-
oncogene encodes a tyrosine kinase transmembrane 
receptor, which is mainly expressed in neural crest-derived 
cell lineages, such as parafollicular C cells, and is involved 
in the control of cell differentiation and proliferation. 
The RET COOH-terminal tail varies in length as a result 
of alternative splicing of the 3′ end, generating three 
different isoforms: RET9, RET43 and RET51. Although 
isoforms share the majority of signalling potentials, 
there are differences in phosphorylation and binding 
of signalling molecules (Myers et  al. 1995, Santoro & 
Carlomagno 2013).
Several murine models have been developed to study 
the pathogenesis and progression of MTC through the 
use of genetic engineering techniques targeting the Ret 
gene (Table 1).
The most available mouse models of MTC were 
generated by tissue-specific expression (mainly in thyroid 
C cells) of mutated Ret gene. Michiels and coworkers 
generated transgenic mouse lines expressing the RET9 
isoform with the MEN2A-associated point mutation at 
codon 634 (Michiels et al. 1997). In these animals, the 
expression of the mutated RET gene was targeted to the 
thyroid C cells under the control of the calcitonin gene-
related peptide (CGRP)/calcitonin (CT) rat promoter. Mice 
expressing the transgene in the thyroid C cells displayed 
bilateral C-cell hyperplasia followed by the development of 
multifocal and bilateral MTC with a complete penetrance 
at 14  months in two transgenic mouse lines, and with 
an incomplete penetrance in one transgenic line. These 
tumours were morphologically and biologically similar 
to human MTC, demonstrating that the short isoform of 
RET is able to drive tumorigenesis in vivo.
Reynolds and coworkers reported that mice carrying 
RET51 isoform with the C634R mutation under the control 
of the human CT promoter developed not only MTC but 
also follicular tumours similar to human papillary thyroid 
carcinoma (Reynolds et al. 2001). These mice developed 
C-cell hyperplasia by 3 months of age (35% of cases), and 
then bilateral MTC by 6–12 months, with a frequency of 
52%, which raised to 68% in mice over 12 months of age. 
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This age-dependent tumour progression resembles the 
situation in MEN2 patients.
In a study using the CGRP-RET C634R model of MTC, 
a strong variation was observed in tumour penetrance 
between mouse background strains, with tumours in 0% of 
FVB/N mice, 14% of BALB/c mice, 64% of C57BL/6J mice 
and 98% of CBA/Ca mice all backcrossed from a single 
transgenic founder (Cranston & Ponder 2003). Tumour 
size positively correlated with the degree of penetrance. 
This study highlights the role of modifier genes in disease 
phenotype and the need for careful consideration during 
selection of mouse background strains (Cranston & 
Ponder 2003).
Acton and coworkers created tissue-specific transgenic 
mice expressing the human RET oncogene cDNA 
encoding the RET9 isoform in which the MEN2B-specific 
M918T mutation was introduced (Acton et al. 2000). In 
humans, MEN2B was almost exclusively associated with 
the M918T alteration in exon 16 of RET gene. In addition, 
M918T is the most frequent RET somatic point mutation 
observed in sporadic MTC (Romei et al. 2016). Transgenic 
mice carrying human RET mutation developed bilateral 
MTC in three out of eight founder lines at 20–22 months 
of age and showed high CT levels (Acton et al. 2000).
Another mouse model for the MEN2B syndrome 
variant was created by Smith-Hicks and coworkers by 
introducing into the mouse Ret gene the M919T codon 
alteration, which corresponds to the M918T mutation 
in humans (Smith-Hicks et al. 2000). The heterozygous 
transgenic mice (RetMEN2B/+) developed thyroid C-cell 
hyperplasia (in 31% of mice at the age of 4–7 months, 
in 55% at 8–12  months); adrenal chromaffin cell 
hyperplasia (in 17% of mice at the age of 4–7 months, 
in 16% at 8–12 months); and pheochromocytoma (in 2% 
at the age of 8–12 months). Homozygous mutant mice 
(RetMEN2B/MEN2B) displayed more severe thyroid lesions 
than to RetMEN2B/+ mice: C-cell hyperplasia (in 86% of 
mice at the age of 6–10 months), which however did not 
progress to MTC; and pheochromocytomas (in 100% of 
mice at the age of 6–10 months). Surprisingly, neither 
multiple mucosal neuromas nor ganglioneuromas of 
the gastrointestinal tract, tumours typically used to 
distinguish between MEN2A and MEN2B, could be 
found in either heterozygous or homozygous mutant 
mice. However, ganglioneuromas of the adrenal 
medulla and enlargement of the associated sympathetic 
ganglia have been observed in 100% of homozygous 
mutant mice. These data suggest that the homozygous 
mice could represent the human MEN2B syndrome 
more closely than the heterozygous ones, showing 
an early incidence and increased severity of C-cell 
hyperplasia and chromaffin cell hyperplasia. However, 
the homozygous mice are different from the human 
MEN2B for two main aspects: they did not develop 
MTC (up to 12 months of age) or ganglioneuromas of 
the gastrointestinal tract.
Altogether, these different genetically engineered 
mouse models provided compelling evidence that specific 
mutations of RET proto-oncogene are oncogenic in 
parafollicular C cells. Moreover, they offer the possibility 
to study the early stages of tumour formation (i.e. 
C-cell hyperplasia), which is very difficult to perform in 
patients and could be useful to test novel drugs capable 
of inhibiting RET function in immunocompetent 
animals. However, there are also few limitations in using 
genetically engineered mouse models, mainly related to 
Table 1 Genetically engineered mouse models of medullary thyroid cancer carrying RET mutations.
RET mutation RET isoform Promoter Background strain Tumor phenotype Reference
C634R RET9 Rat CT C57BL/6J_DBA2 CCH; multifocal and bilateral 
MTC
Michiels et al. (1997)
C634R RET51 Human CT CBA/B6/FVB CCH, bilateral MTC; human 
PTC; exocrine pancreatic 
tumours
Reynolds et al. (2001)
C634R RET51 Human CT BALB/c MTC (14%) Cranston & Ponder (2003)
C634R RET51 Human CT C57BL/6J MTC (64%) Cranston & Ponder (2003)
C634R RET51 Human CT CBA/Ca MTC (98%) Cranston & Ponder (2003)
M918T RET9 Human CT C57BL/6J_DBA2 CCH, multifocal and bilateral 
MTC
Acton et al. (2000)
M919T* (Heterozygous) – – C57BL/6J CCH; adrenal chromaffin cell 
hyperplasia; PHE
Smith-Hicks et al. (2000)
M919T* (Homozygous) – – C57BL/6J CCH; PHE; ganglioneuromas of 
the adrenal medulla
Smith-Hicks et al. (2000)
CCH, C-cell hyperplasia; CT, calcitonin; MTC, medullary thyroid carcinoma; PHE, pheochromocytoma; PTC, papillary thyroid carcinoma.
*Mutation in murine RET gene.
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species-specific differences and to the complexity of the 
human tumour that cannot be reliably mimicked.
CGRP-v-Ha-ras mouse model
RAS is a family of related proteins consisting of small 
GTPases that act as binary molecular switches that 
control intracellular signalling network. They are 
mainly activated through growth factors binding to 
tyrosine kinase receptors, such as RET. Point mutations 
in RAS (mainly H-RAS and K-RAS) have been reported in 
sporadic RET-negative MTC with a percentage varying 
from 0% to 43.3%, suggesting that activation of these 
proto-oncogenes represents alternative genetic events in 
sporadic MTC tumorigenesis (Moura et al. 2015).
Transgenic mice of a C57BL/6 3 SJL strain expressing 
v-Ha-ras in C cells under control of the CGRP promoter 
developed C-cell hyperplasia progressing to MTC in 
85%–93% of animals (depending on founder line) 
between the ages of 6 and 12  months (Johnston et  al. 
1998). Tumours were able to secrete CT. Metastasis 
occurred rarely to the lung and cervical lymph nodes. 
Some tumours had amyloid deposition, cystic cavitation 
and vascular invasion and haemorrhage, characteristic 
features of human MTC. In 4 out of 22 tumours, 
immunohistochemical staining was positive both for 
CT and thyroglobulin. Therefore, this transgenic mouse 
represents an interesting model for investigating the 
role of RAS in the pathogenesis of MTC and also for 
elucidating the mechanisms related to the development 
of mixed medullary-follicular thyroid carcinoma.
Mouse models with mutations in cell-cycle control genes
A significant number of sporadic MTCs resulted to be 
negative for RET or RAS mutations. Therefore, other genes 
also appear to be involved in the pathogenesis of this 
tumour (Romei et al. 2016).
The retinoblastoma (RB) and p53 genes encode 
tumour suppressors that are crucial in the regulation of 
cell cycle. Loss or mutations of these genes have been 
reported in many types of human cancers. It was found 
that mice bearing a single Rb mutant allele (Rb+/−) develop 
pituitary tumours with almost complete penetrance 
(Cote et al. 2015, Kirschner et al. 2016). Rb+/− mice were 
also predisposed to develop C-cell hyperplasia, which 
subsequently progressed into MTC. Depending on the 
specific recombinant mouse mutant used and the genetic 
background, the incidence of these tumours ranged from 
50% to 90% (Williams et  al. 1994, Harrison  et  al. 1995, 
Park et al. 1999, Ziebold et al. 2003). These tumours were 
mostly small, predominantly unilateral and nonaggressive.
Interestingly, Ziebold and coworkers reported that 56% 
of Rb+/− mice with normal p53 status on a 129/Sv 3 C57BL/6 
background developed C-cell hyperplasia or MTC, and rare 
metastases to liver, lung, lymph node and adrenal gland 
(Ziebold et al. 2003). The growth-suppressive properties of 
RB are largely dependent on its ability to regulate the E2F 
transcription factors. The concomitant inactivation of the 
E2F3 transcription factor increases the aggressiveness of 
the MTC yielding metastases at a high frequency.
Another study showed that about 37% of mice (a 
mixed inbred C57BL/6 and 129/Sv genetic background) 
heterozygous for both Rb and p53 mutant alleles (Rb+/− 
p53+/−) developed C-cell hyperplasia and MTC (Harvey 
et al. 1995). Rb+/− and p53+/− mice also developed several 
non-thyroidal neoplasms and had shortened life spans. 
Spontaneous activating mutations of Ret were detected 
in 4 out of 8 MTCs from Rb+/− p53+/− mice (Coxon et al. 
1998). These findings demonstrate the ability of the 
gene knockout model to recapitulate somatic multi-step 
tumorigenesis in MTC.
Recently, a new genetically engineered mouse 
model was generated to determine the role of Rb and 
p53 in MTC carcinogenesis and progression (Akeno et al. 
2015). Mice were developed to target Cre recombinase-
mediated Rb gene ablation under the control of the 
surfactant protein C (SPC) promoted reverse tetracycline 
transactivator. Treatment with doxycycline throughout 
gestation resulted in Rb ablation throughout the lung 
epithelium as well as in a subset of thymic and thyroid 
cells. Double transgenic mice homozygous for floxed 
Rb alleles (designated Rb ablated) developed pulmonary 
neuroendocrine hyperplasia and thyroid tumours 
expressing CT. Moreover, p53 gene was conditionally 
ablated in Rb-deficient thyroid by generating double 
transgenic mice with floxed Rb and p53 alleles. The 
additional p53 loss resulted in dramatic MTC progression. 
Overall, this study demonstrated that Rb loss is sufficient 
to induce thyroid tumours that phenotypically mimic 
human MTC and that although p53 loss is not sufficient 
to initiate neuroendocrine tumourigenesis, p53 plays a 
critical role in suppressing Rb-deficient cancer progression.
RB exerts its tumour suppressor activity through 
interactions with the cyclin-dependent kinases (CDKs), 
which are also inhibited by a family known as the 
CDK inhibitors (CDKNs). Several studies evidenced the 
spontaneous development of C-cell hyperplasia in mice 
lacking CDKN2C (Franklin et al. 2000, van Veelen et al. 
2008) or CDKN1B (Franklin et al. 2000).
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Pozo and coworkers recently generated a mouse 
model, in which MTC proliferation was induced upon 
conditional overexpression of the CDK5 activator, p25, 
in C cells (under the control of the neuron-specific 
enolase promoter) and arrested by interrupting p25 
overexpression (Pozo et al. 2013). Analysis of the 
mechanism demonstrated that p25 overexpression 
led to enhanced CDK5 kinase activity, leading to the 
phosphorylation and inactivation of RB.
However, these models may not faithfully mimic the 
human situation. Indeed, data concerning RB and p53 loss 
in human MTC are scanty and contradictory; therefore, 
their role in the development of spontaneous MTC 
is still unclear (Cerrato et  al. 2009). Holm and Nesland 
(1994) reported in all MTCs (46 cases) a heterogeneous 
RB protein nuclear staining, suggesting that inactivation 
of the RB gene is not important for the pathogenesis of 
MTC. Although in another series, three of the six cases 
of MTC (50%) showed loss of expression of RB protein 
(Anwar et  al. 2000). Using the COSMIC database, 
CDKN2C somatic mutations have been reported in 8% 
of MTC samples (http://cancer.sanger.ac.uk/cosmic). In 
addition, a recent paper showed that the detection of 
somatic CDKN2C loss was associated with the presence 
of distant metastasis and decreased the overall survival in 
a cohort of 62 patients with sporadic MTC (Grubbs et al. 
2016). Eight out of 15 (53%) MTC harboured single point 
mutation or loss of heterozygosity in p53 locus (Pavelić 
et al. 2006). In another series of MTC, allelic loss of p53 
has been reported in 44% of cases (Sheikh et al. 2004).
MTC xenograft murine model
Xenograft tumour models have been widely used as an 
in vivo counterpart to cell lines by cancer researchers. 
In the last years, MTC xenograft mouse model has been 
adopted as preclinical human thyroid cancer model to 
test the efficacy and the safety of several kinase inhibitors.
In most cases, to test the in vivo activity of several 
drugs or drug combination, TT or MZ-CRC-1 cells (both 
human MTC cell lines bearing mutations in proto-
oncogene RET) were inoculated subcutaneously (sc) on 
the back of athymic nu/nu mice. When tumours became 
palpable and mean tumour volume was approximately 
70–80 mm3, animals were randomly divided into control 
group and treated group (Broutin et  al. 2011, Bentzien 
et al. 2013, Lopergolo et al. 2014, Tohyama et al. 2014).
Indeed, a strong antitumor effect of sunitinib and 
other multi-kinase inhibitors, such as vandetanib or 
sorafenib, has been observed in vivo in TT cells implanted 
in mice (Broutin et al. 2011). The antitumor efficacy of 
sunitinib was also tested in mice carrying MZ-CRC-1 
xenografts cotreated with cisplatin, showing that the 
combination of the two drugs was able to effectively 
reduce the tumour mass, resulting in enhanced 
antitumor activity (Lopergolo et  al. 2014). In a recent 
study, the in vivo pharmacodynamic experiments showed 
substantial inhibition of RET in TT xenograft tumours 
after a single oral dose of cabozantinib, a potent RET 
inhibitor. In nude mice, cabozantinib was well tolerated 
and resulted in a dose-dependent tumour growth 
inhibition correlated with a reduction in circulating 
CT levels (Bentzien et  al. 2013). To date, cabozantinib 
and vandetanib have been approved by FDA for the 
treatment of patients with progressive, metastatic or 
unresectable MTC. The antitumor efficacy of lenvatinib, 
a VEGF inhibitor, was also tested in TT xenograft model. 
This molecule showed to inhibit the in vivo tumour 
growth of TT xenografts in a dose-dependent manner. 
Together with the antitumor activity, lenvatinib showed 
a potent inhibition in tumour-induced angiogenesis 
(Tohyama et al. 2014).
These findings provide evidence of xenograft model as 
a potential preclinical model to investigate the antitumor 
activity of new compounds in MTC. However, it should 
be taken into consideration that the transplantation of 
immortalised tumour cell lines provides a simplified 
cancer model with limited applications in the clinical 
setting (Rubio-Viqueira & Hidalgo 2009).
Another type of xenograft model used in research 
is the ‘patient-derived tumour xenograft’ (PDX). This 
model is based on the transfer of primary tumour directly 
from the patient into an immunodeficient mouse. To 
accomplish this, patient tumours must be obtained fresh 
from surgery, at which point they are mechanically 
or chemically digested, with a small portion saved as a 
primary stock, and established in a NOD-SCID mouse. 
PDX models are maintained by passaging cells directly 
from mouse to mouse once the tumour burden becomes 
too high. Tumours can be engrafted heterotopically 
or orthotopically. Heterotopic PDX models involve 
implanting tumours into the subcutaneous flank of a 
mouse. This method allows for easier cell transfer and 
precise monitoring of tumour growth and location (Kim 
et  al. 2009). Orthotopic models are more technically 
challenging and time consuming. This method involves 
the direct implantation to the mouse organ of choice. In 
some cases, additional imaging studies may be needed to 
verify the location of tumour grafts after implantation. 
Orthotopic transplants are considered to more accurately 
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mimic the human tumours from which they are derived 
than heterotopic transplants when comparing histology 
and gene expression profiles from mice to patients. PDX 
models appear to be superior to the implantation of 
cancer cell lines because they maintain more similarities 
to the parental tumours. In addition, PDX represents a 
more physiologically relevant model compared to 2D 
in vitro cellular models, where primary cultures of cancer 
cells grow in suspension culture, or as monolayers on 
plastic surfaces. Indeed, PDX murine models mimic 
more accurately the tumour microenvironment and the 
complex biochemical and physical interactions between 
the cancer cells and the stromal components (Rubio-
Viqueira & Hidalgo 2009). However, for MTC, there are 
serious difficulties to generate a murine PDX model due 
to the slow tumour growth of MTC in most of the cases 
and the low engraftment rate of this tumour in mice, 
representing an important shortcoming for this model. 
This could be the reason why in literature, we found only 
one paper reporting the use of PDX murine model in MTC 
(Gyory et al. 2005).
Drosophila cancer model
In addition to the existing murine models that remain the 
gold standard, other animal organisms have been used in 
the preclinical research on MTC. Even if the number of 
these alternative models is still limited, their applications 
appear suitable and promising.
The fruit fly Drosophila melanogaster has contributed 
significantly in several fields of biology as the genetic 
organism of choice for studying epithelial development. 
In the last years, Drosophila has proven useful in 
establishing genetic models of human diseases due to 
its intrinsic features as the low cost of maintenance, the 
reduced genetic redundancy, the high conservation of 
human signalling pathways and disease genes and the 
ease of mutant flies generation. The fact that Drosophila 
contains functional homologs for the 68% of human 
cancer-related genes, including the proto-oncogene RET, 
has provided a rationale for using this model in tumour 
pathogenesis studies and in anti-cancer drug discovery 
(Yadav et al. 2016). In this frame, Drosophila has been used 
to study MEN2 syndrome by the generation of transgenic 
flies that expressed mutated forms of Drosophila RET 
(dRet) in the developing retina, a neuroepithelial tissue 
that shows remarkable evolutionary conservation of 
receptor tyrosine kinase signal transduction pathways. 
Interestingly, the expression of MEN2A and MEN2B 
analogue mutations led to aberrant cell proliferation 
and inappropriate cell fate specification in developing 
Drosophila retina. Moreover, it has been demonstrated 
that components of the Ras/ERK, Src and JNK pathways, 
previously linked to the vertebrate MEN2 signalling, 
are required for the phenotypic outcomes of dRetMEN2 
activity, thereby validating the Drosophila models (Read 
et al. 2005). Some experiments have taken advantage of 
these transgenic models to perform a screen for genes that 
dominantly suppress or enhance dRetMEN2 phenotypes. 
In this context, sin3a, which negatively regulates the 
transcription of a wide array of genes (van Oevelen et al. 
2008), emerged as a new important mediator of dRetMEN2 
(Read et al. 2005). The dRet transgenic models have also 
been used to quickly and effectively identify compounds 
of potential therapeutic value for MTC. When dRetMEN2B 
larvae were fed vandetanib (Vidal et al. 2005) or sorafenib 
(Das & Cagan 2010), both multi-kinase inhibitors targeting 
Ret induced a suppression of the mutant phenotype. In 
addition, Drosophila models of RET fusions (CCDC6-RET 
and NCOA4-RET) have been recently generated to study 
the specific pathway activated by RET fusion isoforms 
and to test their sensitivity to clinically relevant drugs 
(Levinson & Cagan 2016). This elegant strategy represents 
a new tool to identify the patterns of drug sensitivity for 
each RET isoform.
In conclusion, Drosophila offers powerful tools to 
investigate the molecular basis of MTC and to perform 
high-throughput screening of novel cancer drugs, as 
well as to test multi-targeted agents and combination 
therapy (Dar et  al. 2012, Das et  al. 2014, Yadav et  al. 
2016). However, the employment of Drosophila for 
studies on MTC has several limitations that need to be 
considered. Indeed, the short life cycle can limit the study 
of sequential step-wise changes that usually are specific 
of slow growing tumours, such as MTC. Nonetheless, the 
study of tumour progression, which may rely on tissue-
specific conditions, may be compromised by the lack of 
thyroid and C cells-like structures (Das & Cagan 2010). 
Moreover, given that the anatomy and physiology of flies 
are significantly different from those of mammals, it will 
be important to clarify some issues related to the potential 
efficacy in humans of drugs that have been tested in 
Drosophila (Yadav et al. 2016).
Chick chorioallantoic membrane (CAM)
Among the in vivo models, the chick embryo chorioallantoic 
membrane (CAM) has been used to implant several 
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tumours to study cell proliferation, angiogenic and 
metastatic behaviour and to test the antitumor activity of 
novel compounds (Ribatti 2014).
Yalcin and coworkers adopted this model for MTC. 
Human MTC cells, grafted in the proximity of the chick 
chorioallantoic membrane (CAM), were able to quickly 
stimulate the neovascularisation. In particular, this model 
was used as a parallel platform to xenografts in nude mice to 
confirm the antiangiogenic and antiproliferative effects of 
tetraiodothyroacetic acid on human MTC implanted cells 
(Yalcin et al. 2010). Although the CAM test is a relatively 
simple, quick and cost-saving angiogenesis assay, there 
are also important limitations that must be taken into 
account: (1) a large number of eggs are required to obtain 
consistent results; (2) it could be difficult to distinguish 
tumour-induced vessels from a falsely increased vascular 
density due to rearrangement of existing vessels; (3) 
despite the immaturity of the chick immune system, a 
nonspecific inflammatory reaction can occur particularly 
if experiments are extended after 15 days of incubation 
(Staton et al. 2009, Ribatti 2016).
Zebrafish
Another powerful animal model that can help the 
preclinical research on MTC is zebrafish (Danio rerio). This 
small teleostean fish emerged as a model organism for 
developmental biology studies due to its intrinsic features 
as the high fecundity, the outer fertilisation and the 
conservation of morphogenetic pathways that regulate 
the development of organs from fish to mammals (White 
et  al. 2013). The optical transparency of embryos and 
larvae, together with the availability of transgenic lines 
that specifically express fluorescent proteins in different 
tissue and organs, makes zebrafish a particularly suitable 
model for in vivo imaging of developmental events through 
different microscopy techniques. A growing number of 
publications suggest that zebrafish is a unique in vivo 
system to faithfully recapitulate human cancer through 
carcinogenic induction, transgenesis, gene inactivation 
and xenotransplantation (Huiting et al. 2015).
In this frame, zebrafish could be used to investigate 
the molecular aspects of both pathogenesis and tumour 
progression in MTC. Indeed, zebrafish ret gene encode for 
two isoforms, Ret9 and Ret51, that share high amino acid 
identity with the human counterparts (Marcos-Gutierrez 
et al. 1997, Lucini et al. 2011), in particular, at the level of 
tyrosine kinase domain (Fisher et al. 2006). Recently, the 
presence of two additional novel transcripts in zebrafish, 
RetΔE3 and RetΔE345, previously identified in various 
tumour sources and adult human tissues as a result of the 
skipping of exon 3 or exons 3, 4 and 5 has been reported 
(Gabreski et al. 2016). Commonly used reverse strategies 
to modulate the gene expression (morpholino-mediated 
knockdown, overexpression through mRNA injection 
and transgenesis) and recently developed ret mutants, 
harbouring activating mutations similar to those found in 
patients with MEN2, could provide relevant information 
on the molecular basis of MTC. Moreover, zebrafish 
could offer unique experimental conditions to clarify the 
potential role of C cells microenvironment in the MTC 
pathogenesis (Vitale et al. 2014). Although mammalian C 
cells are located in the thyroid interfollicular spaces, fish 
C cells form the ultimobranchial bodies, an independent 
organ that does not fuse with the thyroid. In zebrafish, 
starting from 60 h after fertilisation, ultimobranchial 
bodies are organised in two groups of cells on either 
side of the heart, in this way, C cells are not in contact 
with thyroid follicles (Porazzi et al. 2009). Thus, zebrafish 
could help us in understanding if extracellular matrix 
components, produced by thyroid epithelial, are necessary 
to the emergence of the MTC phenotype, as previously 
hypothesised in humans (Lekmine et al. 1999).
Another advantage of zebrafish model is offered 
by the possibility to use embryos, larvae and adults to 
perform tumour xenografts of immortalised cell lines or 
patient-derived cell culture, with the main aim of studying 
tumour-induced angiogenesis and invasiveness and 
performing antitumor drug screening. Recently, we have 
developed a system to study MTC-induced angiogenesis, 
based on the injection of human MTC cell lines in the 
Tg(fli1:EGFP)y1 zebrafish embryos that expresses EGFP 
(enhanced green fluorescent protein) under the control of 
the endothelial fli1 promoter, thereby labelling all blood 
vessels and providing a live visual marker for vascular 
development. In particular, we have grafted TT (Vitale 
et al. 2014) and MZ-CRC1 (Fig. 1) cell lines, which harbour 
MEN2A (C634W) and MEN2B (M918T) RET mutations, 
respectively. Red stained MTC cells (100–500 cells for 
embryo) were implanted into the subperidermal cavity 
(between the outer periderm and the yolk syncytial layer) 
of 48 h post-fertilisation Tg(fli1:EGFP)y1 zebrafish embryos. 
We evaluated the proangiogenic potential of grafted cells 
in a short time frame, from 24 to 48 h after injection, and 
without the need of immunosuppression, because the 
immune system is not completely developed during the 
first month of zebrafish life (Tobia et al. 2011). Although 
alterations of vascular network were absent in the control 
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group, consisting of phosphate buffered saline solution 
(PBS)-injected embryos, endothelial structures, sprouting 
from the subintestinal vein (SIV) and the common 
cardinal vein (CCV), were observed in TT- and MZ-CRC1-
grafted embryos (Fig. 1). These endothelial sprouts were 
progressively converted in vessels with heterogeneous 
diameter and length that could rapidly reach the implanted 
tumour cells mass. In these experimental conditions, TT 
cells showed a stronger proangiogenic potential than 
MZ-CRC-1. Indeed, a more intricate network of new 
blood vessels was observed in TT tumour-xenograft within 
24–48 h after injection. In this model, the existence of 
MTC-specific angiogenic signalling pathways can also be 
analysed through a selective knockdown of receptors for 
proangiogenic factors in the recipient zebrafish embryos. 
In this way, it is possible to identify which proangiogenic 
factors, produced by MTC cells, have a predominant 
activity in tumour-induced angiogenesis.
Due to the easy and rapid visualisation of the 
tumour angiogenesis, zebrafish/tumour xenograft 
model represents a valuable platform to test the effects 
of antiangiogenic compounds on tumour-induced 
vascularisation. At the same time, invasiveness of MTC 
cells could be analysed within 2–3 days after the implant. 
Indeed, the transparency of the zebrafish embryos allows 
to follow the very early steps of invasion, circulation of 
tumour cells (stained with a fluorescent cell tracker) in 
blood vessels, colonisation at secondary organ sites and 
metastasis formation in real time. Therefore, this new 
animal model for MTC provides unique tools for the 
visualisation of tumour cell behaviour and interaction 
with host cells.
Zebrafish embryos are readily permeable to small 
molecules dissolved in their culture media. Therefore, 
the zebrafish/tumour xenograft model represents a 
rapid and suitable test to screen small molecules with 
potential antitumor activity and using a small amount 
of compounds, whereas larger or non-water-soluble 
molecules can be injected into the body of the embryo 
to ensure drug uptake. The rapidity of this procedure 
makes this model very useful to perform preclinical drug 
screening, to test and validate new compounds that are 
able to significantly inhibit tumour-induced angiogenesis, 
invasiveness and metastatic dissemination, as already 
described in several tumours implanted in zebrafish 
embryos (Moshal et al. 2011, Goel et al. 2013, Chen et al. 
2015, Zheng et al. 2016).
Recently, our group sets up a method to generate 
PDX of neuroendocrine tumour cells in zebrafish 
embryos to study both the proangiogenic potential and 
the migratory behaviour of grafted cells (Gaudenzi et al. 
2016, Wurth et al. 2016). The appeal of primary cultures, 
instead of immortalised cell line, lies in the conservation 
of both histological and mutational heterogeneity of the 
original tumour (Cassidy et al. 2015). The possibility to 
implant a small numbers of cells (<500 cells for embryo) 
makes the application of PDX in zebrafish embryos 
particularly suitable for neuroendocrine tumours, where 
tumour cells availability is often limited, because of 
the small size of post-surgical samples. In this frame, 
PDX of MTC in zebrafish could represent a promising 
platform to develop new pharmacological treatments 
and to identify information for the most appropriate 
and personalised therapies.
However, there are also few disadvantages of using this 
model (Gaudenzi et al. 2016), that need to be considered, 
such as species-specific microenvironmental differences 
may affect the behaviour of grafted mammalian 
Figure 1
MTC-grafted cells stimulate angiogenesis in zebrafish embryos. Representative confocal microscopic images of Tg(fli1:EGFP)y1 zebrafish embryos 
implanted with red fluorescence-stained MZ-CRC1 (B and D) cells. 24 (A and B) and 48 (C and D) hours after injection (hpi), larvae were embedded in 
low-melting agarose, and the yolk region was observed by confocal microscopy. In comparison to control larvae (A and B), MTC-grafted larvae showed 
endothelial structures (green) that sprout from the subintestinal vein (SIV) plexus and the common cardinal vein (CCV) (B and D) and progressively form 
new vessels. All images are oriented so that rostral is to the left and dorsal is at the top. Scale bar, 50 μm.
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tumour cells; the lack of some mammalian organs in fishes 
(such as mammary gland, prostate and lung) precludes 
the possibility to perform orthotopic transplantation 
experiments; drug metabolism in zebrafish may be 
different from that in mammals; zebrafish embryos are 
maintained at 28°C, this may not represent an optimal 
temperature for mammalian cell growth and metabolism; 
embryonic organs and systems are completely defined but 
their differentiation is incomplete.
Conclusions and future perspectives
Animal models are indispensable tools for investigating 
the pathogenesis, pathophysiology, mechanisms for 
tumour invasion and metastasis and new therapeutic 
approaches for cancer. Unfortunately, only few models 
are available for MTC.
Murine models remain the gold standard for 
preclinical study in MTC. RET transgenic mouse models 
play a relevant role in understanding the pathogenesis 
and progression of this tumour. MTC xenograft mouse 
models are crucial to perform preclinical drug screening, 
but are limited to the implantation of few MTC cell 
lines. PDX represents a more realistic preclinical model. 
Indeed, PDX preserves the original tumour identity, 
reflecting more accurately the complexity of human 
tumour composition, architecture and development. 
However, there are several limitations associated with 
PDX murine model in MTC and in other tumours with 
low proliferation index: low engraftment rates, long time 
required (from several weeks to months) to have a visible 
tumour implant, large number of cells (about 1 million) 
are required to generate a tumour, and high difficulties 
to generate xenotransplant models able to metastasise 
in mouse. In addition, immunosuppressed mice are 
required to avoid transplant rejection, these animals 
are more susceptible to infection and drug toxicity than 
normal mice and need special standards for breeding and 
housing; its laborious and time-consuming process makes 
this model very expensive.
Other animal organisms have been recently 
proposed as alternative or complementary models to 
mice. Zebrafish/tumour xenograft model represents an 
attractive, fast and technically simple model to study 
tumour–host microenvironment, to better characterise 
the multiple mechanisms of angiogenesis and 
invasiveness in MTC and to test in vivo the antitumor 
effects of new compounds. The short generation 
time, the large number of offspring, the transparency 
(enabling  noninvasive  imaging), the external 
development of the embryos and the small size make 
zebrafish a more practical and less expensive laboratory 
system than other in vivo cancer models.
Preliminary data suggest the PDX in zebrafish 
embryos appears to be a reliable in vivo preclinical model 
for neuroendocrine tumours (Gaudenzi et al. 2016, Wurth 
et  al. 2016), opening a future scenario for personalised 
treatment in patients with MTC.
Over the last years, several innovations in 
live imaging of zebrafish embryos have been 
developed to study embryogenesis. In addition to 
the conventional applications in epifluorescence, 
confocal and multiphoton microscopy, zebrafish has 
recently resulted a valid platform for selective plane 
illumination microscopy (SPIM) (Kaufmann et al. 2012), 
a technique that achieves excellent resolution at high 
penetration depth in translucent samples. The most 
prominent advantages of SPIM is the high acquisition 
speed and the reduced photo-toxicity, making this 
technique particularly suitable for long-term time-
lapse experiments in live samples (Huisken & Stainier 
2009). SPIM has been successfully used on zebrafish 
embryos for high-resolution time-lapse imaging of 
developmental processes lasting several hours to a few 
days (Panier et al. 2013, Mickoleit et al. 2014, Bassi et al. 
2015), as shown in Supplementary Video 1, see section 
on supplementary data given at the end of this article. 
In future, this innovative technique could provide 
new information for the study of the tumour–host 
interactions in MTC, with particular interest towards 
tumour-induced angiogenesis and tumour invasiveness. 
Indeed, SPIM would offer the possibility to localise, 
track and register MTC cells and their interactions with 
the local microenvironment.
Finally, all these tumour xenograft models lack the 
innate and adaptive immune system that both play an 
important role in tumour development and progression. 
In this regard, the development of hemato-lymphoid 
humanised models, such as through the cotransplantation 
of MTC cells as well as human immune or stromal cells 
into an immunodeficient animal, may represent a future 
promising strategy for the study of this tumour, especially 
concerning immunological processes and for testing new 
immunotherapies against tumour.
Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
ERC-16-0399.
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